Who We Are

Aplos Medical offers an innovative medical device solution for surgeons to treat GERD patients and enhance their experiences.

CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use.

The Aplos Medical team has a combined experience of introducing over 200 products to the market. These include disposable and implantable medical devices in urology, orthopedics, cardiology, surgery, biologics, in-vitro diagnostics, and more.

Currently, Aplos Medical is focused on a next-era treatment for gastroesophageal reflux disease (GERD) to help physicians improve the lives of patients. We work closely with researchers, manufacturers, clinicians, and others to develop Omega PF™ to be the turning point of GERD treatments in meeting the unmet needs of patients. Our mission is to provide practical, effective, and safe products to benefit patients, medical professionals, and third-party payers.

Aplos Medical Secures 5th NIH SBIR Grant to Launch Pivotal Clinical Trial

We are proud to announce the receipt of our fifth competitive National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant, officially funding the initiation of our pivotal clinical trial.

OUR PRODUCT

A new approach to acid reflux disease.

Omega PF™ is implanted with a straight-forward laparoscopic procedure. The small Ω-shaped device is designed to prevent excessive acid from entering the esophagus while allowing much of the normal swallowing process to remain intact. It is designed to minimize dysphagia and side effects common to other GERD treatments.

LEARN MORE

Digestive Health Kicks Off Clinical Trial With World-First Procedure

New treatment may offer a more efficient path to gastroesophageal reflux disease relief

Reviewed by: F. P. “Tripp” Buckley III, MD, FACS
Written by: Lauren Schneider
The University of Texas at Austin Dell Medical School Blog, August 2023

On August 18, 2023, a new anti-reflux surgical procedure was performed for the first time in history by UT Health Austin board-certified surgeon F. P. “Tripp” Buckley III, MD, FACS, who serves as the Surgical Director of Digestive Health, a clinical partnership between Ascension Seton and UT Health Austin. The surgery was performed as part of a research study evaluating the Omega PF™, a new device developed to treat gastroesophageal reflux disease (GERD).

LEARN MORE
University of Texas at Austin Logo
Start A Conversation

We are seeking partners/investors to help improve the quality of lives for millions of GERD patients with our turning point treatment.

Are you looking for a significant business opportunity? GERD is a multi-billion-dollar market and Omega PF™ is a greatly derisked next-era treatment that is patented in U.S., China, and Europe. It has achieved FDA IDE approval. We are looking for partners/investors to support our FDA-approved clinical studies.

Interested in working with Aplos Medical or learning more about Omega PF™? You can contact us via the information below or fill in the contact form on this page.

Claude Tihon, PhD. | President & CEO
Phone: (952) 944–8718
Click here to Email Claude Tihon, PhD